GW Pharmaceuticals PLC- ADR (GWPH) reported quarterly earnings results on Thursday, May-5-2016. The company said it had a profit of $-0.064 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $-0.09. The company posted revenue of $2.65 million in the period, compared to analysts expectations of $3.80 million. The company’s revenue was down -58.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.03 EPS.
Many Wall Street Analysts have commented on GW Pharmaceuticals PLC- ADR. GW Pharmaceuticals PLC- ADR was Initiated by Numis to “Sell” on Mar 3, 2016. Shares were Reiterated by Leerink Partners on Feb 18, 2016 to “Outperform” and Lowered the Price Target to $ 100 from a previous price target of $129 .
GW Pharmaceuticals PLC- ADR closed down -1.3 points or -1.63% at $78.54 with 4,77,120 shares getting traded on Wednesday. Post opening the session at $80, the shares hit an intraday low of $76.52 and an intraday high of $80 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
GW Pharmaceuticals plc is a United Kingdom-based biopharmaceutical company. The Company is engaged developing a portfolio of cannabinoid medicines including Sativex for the treatment of multiple sclerosis spasticity and cancer pain and Epidiolex for the treatment of childhood epilepsy. The Company also engaged in developing cannabinoids medicines containing controlled substances as well as plant-based prescription pharmaceutical products. The Companys product Sativex is approved in 27 countries and is used as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). The Sativex is also in Phase III clinical development for the treatment of cancer pain the indication for the United States market.